Daily Judi: Friday, August 26, 2022
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
Bloomberg reports that merger negotiations are stalled between Merck and cancer-drug maker Seagen (formerly Seattle Genetics, Inc.) If the deal goes through, it will be Merck's largest in more than ten years.
Clinical Leader details how to improve upon the common goal of prioritizing patient centricity across our entire ecosystem. Jeff Parke writes, "It is vital to promote dialogue, especially among people who may approach the issue from different perspectives. Only then can we overcome the current barriers."
Claudio Fiocchi and Dimitrios Iliopoulos discuss the challenges and need for developing more effective forms of treatments for inflammatory bowel disease. (Journal of Crohn's and Colitis)
Meanwhile, in the New England Journal of Medicine, C. Joseph Ross Daval, J.D., Aaron S. Kesselheim, M.D., J.D., M.P.H., and Ameet Sarpatwari, Ph.D., J.D., argue a consistent approach is needed in how the FDA uses its advisory committees.
The CNS Summit 2022 will be held on November 17–20, in Boca Raton, Florida. Created as "a community of innovators and industry leaders who are not afraid to challenge the status quo," CNS was founded in 2009 to advance clinical development, focused on collaboration and innovation. Team Judi will be there!
We also hope to see you this September 13-14, in Boston, for DPHARM: Disruptive Innovations to Advance Clinical Trials, walking distance from our North End headquarters.
Our Culture
“We create a template so we can pull back the timelines and eliminate concerns around quality and risk—because everything’s already validated in the design.
Then we can work faster with no risk to quality.”
–Jamie, Trial Delivery
About Judi
Judi is on a mission to empower the ecosystems that drive clinical trial success by improving their workflows. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.
